title: [Clinical characters and prognosis of postpartum choriocarcinoma].
abstract: OBJECTIVE
  To analyze the clinical characters and prognosis of postpartum choriocarcinoma.
  
  
  METHODS
  Retrospective analysis of 103 patients diagnosed with postpartum choriocarcinoma in Peking Union Medical College Hospital between 1985 and 2005 was performed.
  
  
  RESULTS
  In a total of 103 cases of postpartum choriocarcinoma treated with multiagent cytotoxic chemotherapy and combined modality therapy, 92 patients (89.3%) achieved a complete remission while 2 patients had a partial remission, and 9 patients died. Regarding 25 cases with chemorefractory choriocarcinoma and 4 relapsed cases, 18 and 3 cases achieved a complete remission respectively. According to the new International Federation of Gynecology and Obstetrics (FIGO) 2000 staging and risk factor scoring system, 17 cases were at FIGO stage I, 8 cases at stage II, 56 cases at stage III, and 22 cases at stage IV. Complete remission was achieved in 100%, 8/8, 95% and 64% respectively. Thirty-five cases in low risk group had FIGO scores < or = 6, and all achieved a complete remission. Of 68 cases in high risk group with FIGO scores > or = 7, 57 (84%) of them obtained a complete remission. There were significant differences in the two groups (P < 0.05).
  
  
  CONCLUSIONS
  Postpartum choriocarcinoma could have an increasing probability of cure with early diagnosis and the use of modern multiagent cytotoxic chemotherapy and combined modality therapy.
authors.affiliation: Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing 100730, China.
authors.forename: Cheng-Zhi
authors.initials: CZ
authors.lastname: Lei
authors.forename: Yang
authors.initials: Y
authors.lastname: Xiang
authors.forename: Xi-Run
authors.initials: XR
authors.lastname: Wan
authors.forename: Jun-Jun
authors.initials: JJ
authors.lastname: Yang
authors.forename: Quan-Cai
authors.initials: QC
authors.lastname: Cui
authors.forename: Feng-Zhi
authors.initials: FZ
authors.lastname: Feng
authors.forename: Xiu-Yu
authors.initials: XY
authors.lastname: Yang
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002822:Choriocarcinoma / Q000188:drug therapy* / Q000601:surgery; D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000097:blood; D003131:Combined Modality Therapy; D003609:Dactinomycin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D049590:Postpartum Period; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000601:surgery
chemical_list: D018997:Chorionic Gonadotropin, beta Subunit, Human; D003609:Dactinomycin; D005472:Fluorouracil